OTCMKTS:MAYNF Mayne Pharma Group (MAYNF) Stock Price, News & Analysis $3.95 0.00 (0.00%) As of 05/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Mayne Pharma Group Stock (OTCMKTS:MAYNF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mayne Pharma Group alerts:Sign Up Key Stats Today's Range$3.95▼$3.9550-Day Range$3.95▼$4.6052-Week Range$2.42▼$4.60VolumeN/AAverage Volume1,887 shsMarket CapitalizationN/AP/E Ratio109.72Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.Read More… Mayne Pharma Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreMAYNF MarketRank™: Mayne Pharma Group scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Mayne Pharma Group. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mayne Pharma Group is 109.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Mayne Pharma Group is 109.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.74. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverMayne Pharma Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMayne Pharma Group does not currently pay a dividend.Dividend GrowthMayne Pharma Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverMayne Pharma Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Mayne Pharma Group this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mayne Pharma Group insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 15.80% of the stock of Mayne Pharma Group is held by institutions.Read more about Mayne Pharma Group's insider trading history. Receive MAYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MAYNF Stock News HeadlinesMAYNF Mayne Pharma Group LimitedApril 25, 2025 | seekingalpha.comMayne Pharma Reports Revenue Growth and New Licensing AgreementApril 21, 2025 | tipranks.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 2, 2025 | Stansberry Research (Ad)Mayne Pharma Faces Legal Challenge from TherapeuticsMDApril 10, 2025 | tipranks.comState Street Corporation Becomes Substantial Holder in Mayne PharmaApril 2, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS) and Mayne Pharma Group (OtherMAYNF)March 4, 2025 | markets.businessinsider.comMayne Pharma expects earnings to triple, shares jump 25pcFebruary 10, 2025 | afr.comDiscover ASX Penny Stocks Featuring Mayne Pharma Group And Two OthersJanuary 30, 2025 | uk.finance.yahoo.comSee More Headlines MAYNF Stock Analysis - Frequently Asked Questions How have MAYNF shares performed this year? Mayne Pharma Group's stock was trading at $2.79 at the beginning of 2025. Since then, MAYNF shares have increased by 41.6% and is now trading at $3.95. View the best growth stocks for 2025 here. When did Mayne Pharma Group's stock split? Mayne Pharma Group's stock reverse split on Wednesday, January 18th 2023. The 1-20 reverse split was announced on Wednesday, January 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Mayne Pharma Group? Shares of MAYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:MAYNF CIKN/A Webwww.maynepharma.com Phone(188) 209-2666FaxN/AEmployees780Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio109.72 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:MAYNF) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mayne Pharma Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mayne Pharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.